WHO ICTRP trial
A randomised, investigator and subject blinded, placebo-controlled study to…
NL-OMON53655 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON53655 |
|---|---|
| Public title | A randomised, investigator and subject blinded, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics of INF904 in healthy subjects after single and multiple ascending doses |
| Scientific title | A randomised, investigator and subject blinded, placebo-controlled study to determine the safety, tolerability, and pharmacokinetics of INF904 in healthy subjects after single and multiple ascending doses - SAD and MAD to assess safety, tolerability and PK of INF904 |
| Primary sponsor | InflaRx GmbH |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | healthy volunteers None;None |
| Interventions | Part 1: Groups 1, 2, 3, 5, 6 or alternative group): The volunteer will be given 3, 10, 30, 60, 90, 120, 180 or 240 mg INF904 or placebo as oral capsule(s) with 240 milliliters (mL) of (tap) water. Group 4: The volunteer will be given 60 mg… |
| Registration date | May 1, 2023 |
| Target size | 86 |
| Secondary IDs | 2022-002765-14;NL82465.056.22 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: